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The mammalian immune system is multicellular in 
composition, and its proper function requires careful 
control over complex developmental pathways and 
many distinct types of effector responses. Numerous 
overlapping mechanisms of intercellular communi­
cation are needed to accomplish the tasks of proper 
regulation of the diverse cell types that constitute 
this essential protective system. One mechanism oc­
curs by direct cell-to-cell contact through the inter­
action of membrane-associated molecules. Examples 
of this type of communication include the interaction 
that takes place between the antigen-specific T-cell 
receptor and the foreign peptides that are bound to 
major histocompatibility complex molecules, as well 
as co stimulatory molecule interactions with their 
specific ligands expressed on antigen-presenting cells 
(e.g., CD28 and B7-1 or B7-2). A second mechanism 
occurs through the production, secretion, and activ­
ities of soluble mediators, collectively known as the 
cytokines. The cytokines are represented by a large 
and diverse group of molecules that are produced by 
a wide variety of cell types. Unique species of cyto-
T he primary objective of this review is to present some recent experimental evidence that supports the con­cept that various species of steroid hormones can serve important immunoregulatory functions in vivo. The mechanisms involved in these processes include 
not only the classic steroid-hormone-receptor complex regulation 
of gene transcription. but also the tissue-specific end-organ metab­
olism and/or catabolism of circulating steroid hormones. These 
latter enzymatic processes. so important to many essential physio­
logic mechanisms in vivo [1-4], provide a biochemical means to 
create unique transcriptional regulatory microenvironments within 
specific lymphoid tissues. The preferential development of hu­
moral, cellular, cytotoxic, or a common mucosal immune response, 
all of which might occur after a host encounter with an antigenic 
substance, may be controlled by the regulatory processes residing 
within, and unique to, the secondary lymphoid organ where 
antigen-specific lymphocyte stimulation is occurring. Some of these 
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kines bind to specific membrane-associated receptors 
on target cells, inducing the activation of particular 
signal-transduction pathways. These processes subse­
quently lead to the' diversity of cytokine-linked 
changes in cellular physiology. Some of the cytokines 
exert their influences in vivo via endocrine routes, 
although it is far more common for intercellular 
communication via cytokines to occur micro environ­
mentally via paracrine or autocrine pathways. The 
object of this review is to provide evidence support­
ing the concept that one mechanism for upstream 
regulation of cytokine production by immunocom­
petent cell types is controlled by the regulatory ac­
tivities of various steroid hormones. Strain variation 
in susceptibility to infectious agents, the condition of 
immunosenescence, and the processes that control 
the development of common mucosal immunity are 
used as examples of immune mechanisms that may be 
under steroid hormone control. Key words: Cytokinesl 
dehydroepiandrosteronel1 a,25 dihydroxyvitamin D3lgluco­
corticoids. ] Invest Dermatol 105:148-198, 1995 
regulatory processes may be effected through the well-described 
actions of the natural steroid hormones. 
We chose three distinct and well-recognized conditions as 
examples to support our working hypothesis concerning the in­
volvement of steroid hormones in the early afferent decision­
making phases of an immune response. The first addresses the 
well-documented di1ferences in infectious-disease susceptibility be­
tween the BALB/c mouse and other mouse strains. It is well 
documented that BALB/c mice elicit a type 2 response (dominated 
by interleukin [IL]-4 and IL-10) after challenge with many intra­
cellular pathogens. For example, after an experimental infection 
with Leishmania major, BALBI c mice develop severe disease be­
cause they are incapable of clearing the infection [5]. This is 
contrary to what is observed with mice of the C57BLl6 and C3H 
strains, which generate a type 1 response (dominated by IL-2 and 
interferon [IFN]-y) to many types of infectious agents and readily 
resist an experimental challenge with L. major. Presently, no 
information exists to explain adequately the animal strain specificity 
to these di1ferential responses. Why a host responds to an infection 
in a particular manner represents an important basic question in 
immunobiology because there are a number of human conditions 
that produce wide variations in responsiveness to particular infec­
tious challenges. In most cases, these qualitative di1ferences in 
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responsiveness are directly linked to the pathology of the disease 
[6) . The murine models described above are believed to represent 
valid animal counterparts to the human situation . 
The second condition that we will cover relates to the well­
documented decline in immune function that accompanies aging 
[7,8]. This condition, termed "immunosenescence" by investiga­
tors in the field, appears to be linked to well-defined changes in the 
types of cytokines capable of being produced by T cells in response 
to stimulation [7,9]. At the present time, there is no consensus as to 
the causes of the immunosenescent phenotype or to possible 
solutions or therapeutic interventions. This condition, which affects 
most elderly individuals to some extent, plays a very significant role 
in infectious-disease susceptibility, length and severity of the illness 
caused by an infection, and in the markedly reduced efficiency of 
protective vaccination in elderly people [8]. These changes in 
immunocompetence are not only respons�ble for declines in the 
quality of life, but also contribute significantly to the very high cost 
of health care in older people. 
The final condition to be discussed involves the present percep­
tion that certain factors are necessary to induce the development of 
a common mucosal immune response. Secretory immunity, by 
which mucous membranes are bathed with antibodies capable of 
influencing the colonization of potentially infectious microorgan­
isms, is thought to be an essential component of the arsenal of the 
mammalian immune system [10,11]. It is presently accepted that 
the induction of common mucosal immunity in response to an 
antigen requires that the antigen be presented across a mucosal 
surface that is afferent to the lymphoid organs serving as the 
"mucosal immunity inductive sites." These secondary lymphoid 
organs (e.g., Peyers patch) are unique in that they harbor T cells 
which, upon activation, produce the pattern of cytokines necessary 
for stimulating B-cell di1ferentiation down the pathways important 
for common mucosal immunity. 
The development of common mucosal immune responses is 
complex in that immune cells must acquire the capacity to produce 
appropriate types of immunoglobulins, as well as acquire the 
cell-surface structures needed for tissue localization into specific 
regions of mucosal tissues [10,11]. Currently , the experimental 
systems capable of promoting or augmenting the development of 
common mucosal immunity are problematic and would not be 
acceptable in human medicine. Methods designed to overcome the 
limitations associated with the development of common mucosal 
immunity are extremely important because the vast majority of 
microorganisms capable of causing disease gain access to a suscep­
tible host by passage across some mucosal surface. The ability to 
promote the induction of common mucosal immunity therapeuti­
cally after vaccination would provide an added defense mechanism 
against mucosal tissue acquired infections . 
We hope to demonstrate in this review that murine strain 
variations in susceptibility to infectious diseases, the condition of 
immunosenescence, and the requirements for promoting common 
mucosal imm�ty each represent situations in which the mecha­
nisms are susceptible to the regulatory influences of specific steroiq 
hormones. Reduced rates of end-organ catabolism of glucocorti­
coids within peripheral lymphoid organs may partially explain why 
BALBI c mice preferentially exhibit type 2 responses to antigen 
stimulation. The age-associated loss in the endogenous productic;m 
of the steroid dehydroepiandrosterone sulfate (DHEAS) appears to 
be a contributing factor to the age-associated changes leading to the 
immunose�escent phenotype. Finally, the end-organ metabolism of 
vitamin D3 in mucosal tissue-draining lymphoid organs may be 
capable of creating the regulatory microenvironment within sec­
ondary lymphoid organs most appropriate for promoting the de­
velopment of common mucosal immunity. 
RESULTS 
Can Strain-Specific Differences in Infectious-Disease Sus­
ceptibility Be Linked to Variations in Glucocorticoid Me­
tabolism? L. major is a protozoan parasite that establishes resi­
dence within host macrophages. After infection with this parasite, 
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most inbred strains of mice develop a localized cutaneous lesion 
that heals spontaneously . However, some strains of mice, with 
BALBI c being the prototypic strain, develop a disseminated vis­
ceral infection that leads to the eventual death of !h.e animal [5]. 
Type 1 immunity has been identified as important in promoting 
L. major resistance , and T cells isolated from infected, spontane­
ously healing C3H-strain animals produce type 1 cytokines after 
activation with L. major antigens in vitro. Lymphoid cells from 
infected BALBlc animals, however, produce a type 2 pattern . In 
vivo, the protective role of IFN-/, was established by finding the 
conversion of normally resistant C3H animals to a non-healer 
phenotype after administration of anti-IFN-/, antibodies at the time 
of L. major challenge [12]. Alternatively, BALBlc animals can be 
converted to the healer phenotype by injecting a monoclonal 
anti-IL-4 antibody at the time of Leishmania challenge [13]. 
Expression of type 1 or type 2 cytokine responses also appears to 
play a role in the development or progression of various human 
diseases . Included on this list are human immunodeficiency virus, 
tuberculosis, and leprosy [14-16]. More specifically, infection with 
the intracellular pathogen Mycobacterium /eprae manifests itself either 
as a well-confined lesion (tuberculoid leprosy) or disseminated, 
multifocal disease (lepromatous leprosy) . The tuberculoid or resis­
tant form or" disease correlates with the ability to produce type 1 
cytokines, whereas the expression of lepromatous leprosy is related 
to the host's ability to elicit only the type 2 pattern of cytokines 
[16]. 
The development of either a predominant type 1 or type 2 
cytokine response by di1ferent individuals or different strains of 
mice appears to be inherently regulated . We have observed that in 
polyclonally activated T cells obtained from C3H or BALBI c mice, 
there is a di1ferential propensity to produce either a type 1 or type 
2 pattern of cytokines, respectively (Fig lA). Spleen and lymph 
node cells isolated from C3H animals produce greater quantities of 
IL-2 and IFN-/, than ofIL-4 or IL-l0, whereas the activation ofT 
cells from BALBlc mice results in greater levels ofIL-4 and 1L-10 
than of IL-2 or IFN-/,. However, the fundamental question as to 
what accounts for the different types of cytokine responses elicited 
by C3H and BALBI c mice has not been resolved. 
Glucocorticoids are known to modulate a number of immuno­
logic processes in vivo [17,18]. One such effect involves the 
regulation of cytokine gene transcription in a positive or negative 
manner [19-21]. Our laboratory has shown previously that the 
administration of dexamethasone to animals resulted in a dimin­
ished capacity of antigen-activated T cells to produce IL-2 and 
IFN-/, [21]. Under these same conditions, the amount of IL-4 
produced by these cells was significantly enhanced. We have also 
observed that spleen and peripheral lymph node cells isolated from 
C3H mice produced lower levels of IL-2 and IFN-/, and higher 
levels of IL-4 after their stimulation in the presence of physiologic 
levels of corticosterone (10-7 to 10-8 M) (data not shown) . From 
these observations, it became apparent that exposure of murine 
lymphoid cells to physiologic concentrations of corticosterone 
during activation resulted in a cytokine protile that was similar to 
that normally observed from BALB/c lymphoid cells after their 
activation. Therefore, it seemed reasonable to speculate that the 
plasma concentration of corticosterone in BALBI c animals might 
pe higher than the corticosterone levels found circulating in C3H 
animals. However, an experimental analysis revealed that the levels 
of plasma corticosterone did not vary between the C3H and 
BALB/c strains of mice (data not shown) . 
Other mechanisms exist that can vary the concentration of active 
glucocorticoids within tissues . llf3-hydroxysteroid dehydrogenase 
(11f3-HSD) is a tissue enzyme capable of efficiently converting 
biologically active glucocorticoids to their inactive ll-keto forms 
(cortisol to cortisone, or corticosterone to ll-dehydrocorticoste­
rone) [2]. Normal kidney and testicular physiology is strictly 
dependent on the activity of llf3-HSD [3,4]. Kidney cortical 
collecting duct epithelium possesses mineralocorticoid receptors 
capable of being activated by either cortisol or aldosterone equiv­
alently. Kidney llf3-HSD effectively converts all duct epithelium 
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Figure 1. Strain-specific variations in cytokine p,roduction by 
lymphocytes from C3H and BALB/c mice appeu to be unde,r 
glucocorticoid control. Lymphocytes isolated from the spleens of C3H 
or BALBI c mice were stimulated in vitro with anti-CD3e antibody as 
described previously [9]. After 24 h. culture supernatants were collected and 
analyzed quantitatively by enzyme-linked immunosorbent assay for ll.-2. 
IFN-y. IL-4. and IL-l0 (A). Lymphoid organ stroma from spleen, peripheral 
lymph node (PLN), and thymus was separated from the lymphoid cell 
components. Microsomal preparations were prepared from each tissue and 
analyzed for l1j3-HSD activity according to the protocol of Marandici and 
Monder [38]. l1{3-HSD activity is expressed as the percent conversion of 
3H-corticosterone to ll-dehydrocorticosteronel250 J,Lg microsomal pro­
teinlh (B). 
cortisol to cortisone, a metabolite that is incapable of binding to the 
mineralocorticoid receptor and is actively transported out of the cell 
[2,22]. This end-organ catabolic process prevents cortisol, which 
circulates at a tOOO-fold higher level than aldosterone, from 
abnormally activating the mineralocorticoid receptor. A similar 
type of end-organ catabolism takes place in the testes, where 
11{3-HSD protects Leydig cells from the inhibiting endogenous 
circulating concentrations of glucocorticoids [4]. Because 11 {3-
HSD can be expressed in a variety of tissues. we hypothesized that 
it may play a role in regulating glucocorticoid activities in distinct 
lymphoid tissues in vivo [23]. 
Our laboratory has recendy found 11 {3-HSD residing within both 
primary and secondary lymphoid organs. We predicted that varia­
tions in l1{3-HSD could be acting as a lymphoid tissue regulator of 
bioactive glucocorticoid concentrations in specific tissues. Signifi­
c�t 11{3-HSD activity was observed in the spleen, peripheral 
lymph nodes, and thymus (data not shown). When spleen. lymph 
node, and thymus of normal-mice preparations were divided into 
stromal and lymphoid cell fractions and analyzed for l1{3-HSD 
activity. most of the enzyme activity was found to reside in the 
stromal cell fraction (data not shown). A similar situation has been 
reported in the kidney, testes, and brain, where only specific 
regions of these tissues possess l1{3-HSD activity [24-26]. A 
comparative analysis oflymphoid organ stroma from spleen, lymph 
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node, and thymus tissues from C3H and BALBI c mice established 
that both lymph node and spleen ll/3-HSD activity was signifi­
candy higher in the stroma of C3H mice than in the stroma of 
BALBlc mice (Fig IB). We have consistendy observed a 3-4-fold 
higher rate of conversion of corticosterone to 11-dehydrocortico­
sterone by stromal cell preparations obtained from peripheral 
lymph nodes of C3H mice as compared with BALBlc mice. It is 
surprising that the level of 11f3-HSD activity in the thymus was 
similar in both strains of mice. We have also observed that the 
11 {3-HSD activity present within a number of nonlymphoid organs, 
including the liver and lungs, is also significantly higher in C3H 
mice than in BALBI c animals. Our data support the concept that 
the variation of 11f3-HSD activity in peripheral lymphoid organs of 
C3H and BALB/c animals inBuences immune outcomes. Lower 
rates of glucocorticoid �atabolism could �reate a microenvironment 
that selectively promotes a type 2 cytokine pathway, whereas 
higher rates of glucocorticoid catabolism would lower active 
glucocorticoids withjn lymphoid tissues and favor type 1 cytokine 
pathways. 
What Is the Relation Between Immunosenescence and the 
Endocrinologic Changes That Occur With Aging? Most 
organ systems of the body undergo some form of age-associated 
change, and there are many examples in which such changes show 
a direct linkage to degrees of compromise to a particular organ 
systems' function. The mammalian immune system, with its many 
high-profile effector responses that are associated with host protec­
tion and sometimes host pathology, represents a complex organ 
system that undergoes very marked functional changes during the 
aging process. Most animals begin life with suboptimal (function­
ally immature) immune systems. Because of a combination of 
genetically controlled developmental processes integrated with life 
experiences, the immune syst�m matures to provide an exceptional 
array of protective effector mechanisms. Optimum immune func­
tion is maintained during the life of an animal for periods that 
generally extend beyond the time of reproductive competence of 
the species. In the elderly, especially those individuals who are both 
chronologically and physiologically old, the immune system loses 
much of its protective potential, producing a greater susceptibility 
to infectious disease, autoimmune-type conditions, and even cancer 
[8,27]. 
The mechanisms responsible for causing the age-associated de­
clines in immunocompetence have not yet been investigated ex­
haustively. Regardless, a number of significant observations have 
been made concerning physiologic changes that could contribute to 
the immunosenescent phenotype, with some representing logical 
targets for further experimental investigation. The consensus is that 
aging does not cause significant changes in the overall cellularity, 
lymphoid organ distribution, or cell subset composition (B cell, T 
cell. macrophage) of the various cell types involved in immune 
responses [7-9]. A couple of notable exceptions are the depressions 
in T cells bearing CD45R as a marker of the "naive" phenotype, 
and the oligoclonal increase in the absolute number of B cells 
bearing the B-1 phenotype [7,28]. However, the functional prop­
erties of the cellular elements of the aged immune system are 
affected in very significant ways. Proliferative and calcium re­
sponses to stimulation are markedly reduced in activated T cells 
from aged donors, and the types of lymphokines produced in 
response to stimulation are qualitatively different, with significant 
depressions in IL-2 and concomitant increases in other cytokine 
species (e.g., 1L-4, IL-S, IL-6, IL-10, and IFN-'Y) [9]. These 
profound qualitative changes in antigen-driven lymphokine pro­
duction could explain many of the altered immune effector re­
sponses of the elderly, including those related to decreases in 
cellular and humoral innnunity [7-9]. 
Our initial research interest in the area of geriatric immunology 
derived from observations that T lymphocytes exposed to low 
concentrations of the steroid dehydroepiandrosterone (DHEA) 
produced far greater quantities ofIL-2 after activation through the 
T-cell receptor than did activated control T cells [29]. Because it is 
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Figure 2. The incorporation of DHEA into vaccine formulations 
can overcome immunosenescence. Groups of mature adult (14-16 
weeks) and aged (26 months) C3H/HeN mice were injected intramuscu­
larly with 0.1 ILg of influenza virus vaccine (Beijing strain) in 25 ILl of saline 
containing 6 p,g of alum. Half of the aged animals received a dose of2.0 ILg 
ofDHEA incorporated directly into the vaccine. The booster immunization 
with virus antigen only was given at day 36. Antibodies from the serum of 
individual animals were quantitated by enzyme-linked immunosorbent 
assay. 
well accepted that the endogenous production of this naturally 
occurring steroid declines significantly with advancing age [9,30], 
we wondered whether any aspect of immunosenescence was due to 
changes in the production ofDHEA or its sulfated derivative. We 
chose DHEAS for our initial animal supplementation studies be­
cause we had already reported that site-specific conversion of 
DHEAS to DHEA in vivo was probably involved in creating the 
unique differences between peripheral and mucosal lymphoid tissue 
microenvironments, where resident T cells are either in a type 1 or 
type 2 physiologic state [30,31]. When aged animals were provided 
oral supplementation with DIiEAS (approximately 2- 4 mg/kg/d) 
and assayed for immunocompetence, it was observed that norm,u 
mature adult patterns of inducible T-cell lymphokines were re­
stored in all lymphoid organs tested, and, more important, the 
supplemented animals were able to promote the generation of solid 
humoral immune responses to protein antigens [9]. Based on these 
studies, other investigators have now reported that DHEAS sup­
plementation of old animals also enhances their capacity to produce 
antibodies to pneumococcal polysaccharide [32] and to other 
protein antigens [33,34]. The mechanisms responsible include the 
better development of lymph node germinal centers [33] and a 
restored ability of T cells from supplemented animals to express Fe 
receptors for IgD [34]. 
Our own research has recently moved in the direction of using 
the immunomodulatory properties of DHEA to enhance vaccina­
tion efficiency in age-compromised hosts. Aged animals given small 
amounts ofDHEA by topical application or direct injection afferent 
to a particular lymph node temporarily corrected the potential of 
their T cells residing with the draining lymph node to produce a 
mature adult pattern oflymphokines after activation [9,30]. T cells 
residing within the contralateral lymph node were unaffected by 
this localized treatment and retained the aged phenotype of lym­
phokine production. The direct incorporation of2-20 I-tg ofDHEA 
or DHEAS into a protein vaccine formulation has subsequently 
been found to promote the generation of very respectable titers of 
serum immunoglobulin in age-compromised hosts [30]. Figure 2 
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shows an example of this type of experiment, in which 2.0 I-tg of 
DHEA has been added directly to a vaccine prep aration containing 
0.1 I-tg of inactivated influenza virus protein. The results demon­
strate that very old (26-30 months) C3H mice can be immunized 
successfully with this antigen-DHEA formulation under conditions 
in which aged control animals fail to respond . Further, recall 
responses to the secondary administration of antigen alone (surro­
gate infection) were elicited only in the aged animals provided with 
the vaccine plus immunomodulator to elicit primary responses . We 
have repeated this type of experiment numerous times with a 
variety of protein and protein-polysaccharide conjugate vaccines . 
In every study, normal aged animals vaccinated with an antigen 
formulation containing DHEA or DHEAS were able to respond, as 
evidenced by high titers of specific antibodies. These antibodies can 
be highly protective, as aged animals vaccinated with tetanus toxoid 
plus DHEA were able to neutralize a challenge with tetanus toxin. 
Vaccinated aged animals without DHEA addition were very sensi­
tive to toxin challenge (data not shown) . 
Our findings are consistent with the hypothesis that elderly 
individuals become refractory to effective vaccination partially 
because oflosses in the ability to produce adequate amounts of the 
immunoregulatory steroid DHEA. At present, the mechanisms 
responsible for the positive influence of this steroid on antibody 
production in elderly animals is not fully understood. There have 
been reports that DHEA can influence IL-2 production by activated 
T cePs or exert antiglucocorticoid activities in vitro or in vivo, and 
these mechanisms may be involved in its positive effects on immune 
system function. 
We presently favor the concept that DHEA is produced locally 
from its circulating hydrophilic prohormone DHEAS. This process 
of site-specific end-organ metabolism provides a means to restrict 
anatomically the presence, and therefore the activity, of bioactive 
steroid hormones that circulate normally in nonactive or weakly 
active storage forms [3S]. This process of conversion of an inactive 
precursor to an active steroid species is opposite to that which 
occurs with glucocorticoids, whereby site-specific protection from 
glucocorticoid influences occurs via tissue-specific differences in the 
rate of its end-organ catabolism. 
Manipulation of the Common Mucosal Immune System 
With Steroids T cells residing within the Peyers patches, or 
other lymphoid organs that receive afferent lymphatic drainage 
from mucosal tissues, are known to play unique roles in promoting 
the development of secretory immune responses [10]. These T 
cells, as components of the recirculating lymphocyte pool, appear 
to be programmed for the predominant production of those 
lymphokine and cytokine species important for promoting the 
development of common mucosal immune responses when in 
residence within mucosal lymphoid tissues [10,35]. The cytokines 
important for promoting the development of secretory immunity 
include 1L-4, IL-S, IL-6, and IL-I0 [11]. We recently demonstrated 
that these molecules represent the major products produced after 
polyclonal T-cell activation of lymphocytes obtained from most 
mucosal lymphoid organs [30,31] . 
la,2S dihydroxyvitamin D3 [1,2S(OHhD3] is a steroid hormone 
that is extremely important for the normal functioning of many 
physiologic processes in vivo. This hormone is end-organ metabo­
lized from circulating 2S-hydroxyvitarnin D3 by the actions of the 
inducible enzyme 1a hydroxylase [36]. This process provides a 
means to localize microenvironmentally the effects ofl,2S(OH)2D3 
to cells within tissues where its inactive precursor is being metab­
olized . Both lipopolysaccharide and IFN-'Y r epresent effective 
stimulants of 1 a hydroxylase activity in human macrophages. 
We have observed recently that murine T cells exposed to 
1,2S(OHhD3 undergo a number of changes in the patterns of 
cytokines capable of being produced after their activation. The 
production of IT..-2 and IFN-'Y was markedly depressed, whereas 
treated T-cell production of IL-4, IL-S, and 1L-10 was greatly 
enhanced. An example of such an experiment is presented in Fig 3 
and demonstrates that l,2S(OHhD3 can transform a normally type 
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Figure 3_ Vitamin D, can switch a type 1 dominant response into 
one dominated by type 2 cytokines. Lymphocytes were isolated from 
the spleens or peripheral lymph nodes (PLNC) ofC3H/HeN mice and were 
stimulated ill vitro with anti-CD3E antibody in the presence of various 
amounts of1,25(OH),D3, as described previously [4,29]. Supernatants were 
harvested after 24 h and analyzed quantitatively for IL-2, IFN-'Y, IL-4, and 
IL-l0 by enzyme-linked immunosorbent assay. The data presented are 
representative of three diJferent experiments. 
1 pattern of cytokines into a type 2 pattern. The results of these 
studies, in which murine T cells were manipulated in vitro, have 
now been extended to question whether similar changes in cyto­
kine production can be accomplished in vivo. Three hours after the 
topical application of 1 /kg of 1,25(OHhD3 to one forepaw of 
normal adult C3H mice, the draining and contralateral lymph nodes 
were collected, and the lymphoid cells obtained from these tissues 
were polyclonally activated i,t vitro with anti-CD3e. The lympho­
cytes draining the site of topical steroid application were altered to 
produce a typical type 2 pattern of cytokines, whereas activated T 
cells from the contralateral control lymph node expressed the 
normal type 1 pattern [37]. The results of this study suggest that it 
may be possible to manipulate the microenvironmental infiuences 
within a peripheral lymph node to mimic conditions normally 
restricted to a Peyers patch microenvironment in vivo. A number of 
experiments have now been conducted to test this hypothesi-s, 
including the one presented in Fig 4. In this study, normal C3H 
mice were vaccinated with 0.1 /kg of inactivated infiuenza virus in 
contrpl formulations and in formulations that also contained 
DHEA, t,25(OH)2D3' or a combination of both steroids. The 
results of antibody assays on serum and diluted vaginal lavage fluids 
established that 1,25(OH)2D3' added to a vaccine formulation 
administered parenterally, uniquely promoted the added produc­
tion of mucosal antibodies. The combinatiQn of DHEA and 
1,25(OH)2D3' as coadministered immunomodulators, greatly en­
hanced the titer of both serum and mucosal antibodies (Fig 4A,B) 
and also promoted the generation of an immune response cap�ble 
of protecting the animals against an influenza virus challenge 
administered 12 weeks after initial vaccination (Fig 4C). The 
results of these studies suggest that it may be feasible to promqte the 
development of common mucosal immunity after a controlled 
parenteral administration of vaccine antigen using a steroid-hor­
mone-modulated immunization strategy. 
SUMMARY 
The. results of the studies presented in �s review have experimen­
tally questioned the following: 1) animal strain di1ferences in 
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Figure 4. The incorporation of appropriate steroid immunomodu­
lators into vaccine preparations promotes the induction of com­
mon mucosal immunity after a parenteral immunization. Groups of 
normal, mature adult C3H/HeN mice were immunized with 0.1 f,Lg of 
inactivated Beijing strain infiuema virus vaccine. Subgroups received either 
vaccine alone or vaccine formulations containing DHEA, 1,25(OHhD3' or 
DHEA and 1,25(OH)2D3· IgG and IgA antibodies were quantitated from 
the serum (A) and mucosal secretions (B) 28 d after immunization. Vaginal 
lavage liuids served as the source of mucosal secretions in the study, 
although lung lavage liuids provide similar results. All vaccinated animals 
were challenged with 150 plaque-fonning units of inliuenza virus at 12 
weeks after vaccination, and nasal lavage fluids were assayed 3 d later for 
virus. 
immune competence, 2) the immunobiology of aging, and 3) the 
conditions needed to generate common mucosal immunity. Col­
lectively, the results suggest that it may be possible to control 
therapeutically the type(s) and intensity of immune responses 
elicited to an antigen challenge in vivo. We now appreciate that 
di1ferent species of steroid ltormones might be useful as immuno­
modulators because of their ability to exert unique regulatory 
properties on cytokine production by T cells and other lYmphoid 
cells. It is possible that some �fthese steroili-controlled mechanisms 
may operate naturally in· vivo to sway the balance of immune­
efi'ector pathways between humoral and cellular immunity. The use 
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of substances such as selected steroid honnones, which are capable 
of preferentially prioritizing antigen-driven T-cell responses down 
a type 1 or type 2 dUferentiation pathway of cytokine production, 
may ultimately prove useful in guiding the development of the best 
possible types of e1fector immune responses after an antigen 
challenge. This would be helpful in situations of vaccination, 
especially under those conditions in which host responsiveness is 
compromised or the specific nature of protective e1fector immune 
responses is crucial. 
This work was fimded by National Institutes of Health Grants CA259 1 7  and 
AG1 1475 and by DVA Medical Research Funds. 
REFERENCES 
1. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CHL, Edwards 
CRW: Mineralocorticoid activity of liquorice: l 1 ,8-hydroxysteroid dehydro­
genase deficiency come of age . Lancet II:821-824, 1987 
2.  Monder C, White PC: 1 1 ,8-hydroxysteroid dehydrogenase. Vitam Horm 47:1 87-
271, 1993 
3 .  Stewart PM, Corrie JET, Shackleton CHL, Edwards CRW: Syndrome of 
apparent mineralocorticoid excess: a defect in the cortisol-cortisone shutde. ] 
Qin Invest 82:340 -349, 1988 
4. Monder C, Hardy MP, Blanchard RJ, Blanchard DC: Comparative aspects of 
1 1,8-hydroxysteroid dehydrogenase. Testicular 1 1,8-hydroxysteroid dehydro­
genase: development of a model for the mediation of Leydig cell fimction by 
corticosteroids. Steroids 59:69-73, 1994 
5. Sher A, Collinan RL: Regulation of immunity to parasites by T cells and T-cell 
derived cytokines. A,mu Rev ImmunoI 1 0 :385-409, 1 992 
6. Paul WE, Seder RA: Lymphocyte responses and cytokines . Cell 76:241-2 5 1 ,  
1994 
7. Thoman ML, Weigle WO: The cellular and suhcellular basis of immunosenes­
cence. Adv Immunol 46:221-261, 1989 
8. Schwab R, Waiters CA, Weksler ME: Host defense mechanisms and aging. 
Semi" OncoI 16:20-27, 1989 
9. Daynes RA, Araneo BA: Prevention and reversal of some age-associated changes 
in immunologic responses by supplemental dehydroepiandrosterone sulfate 
therapy. Aging: Immunol byeet Dis 3:135-1 54, 1992 
10.  McGhee J, Mestecky J, Dertzbaugh M, Eldridge J, Hirasawa M, Kiyono H: The 
mucosal immune system: from fimdamental concepts to vaccine development. 
Vaccine 1 0:75-89, 1992 
1 1 .  Husband A: Novel vaccination strategies for the control of mucosal infection. 
Vaccine 1 1 : 107-1 12,  1 993 
12. Scott P: IFN-gamma modulates the early development ofTh1 and Th2 responses 
in a mutine model of cutaneous leishmaniasis.] ImmunoI 147:3 149-3155,  1991 
13.  Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM: Cure 
of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence 
for a T cell-dependent, interferon gamma-independent mechanism.] Exp Med 
171:115-127, 1990 
14. Clerici M, Hakim FT, Venzon DJ, Blatt S, Hendrix CW, Wynn TA, Shearer 
GM: Changes in interleukin-2 and interleukin-4 production in asymptomatic, 
human immunodeficiency virus-seropositive individuals. ] Clin Illvest 91:759-
765, 1993 
15. Orme 1M, Roberts AD, Griffin ]p, Abrams JS: Cytokine secretion by CD4 T 
lymphocytes acquired in response to Mycobacterium tuberculosis infection. ] 
ImmunoI 1 51 : 5 1 8 -525, 1993 
16.  Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, 
Modlin RL: Defining protective responses to pathogens: cytokine profiles in 
leprosy lesions. Science 254:277-279, 1991 
ENDOGENOUS IMMUNE REGULATORS 19S 
17. Cupps TR, Fauci AS: Corticosteroid-mediated immunoregulation in man. 
Immunol Rev 65:133-1 55, 1982 
18. DiRosa M, Radomski M, Camuccio R, Moncada S: Glucocorticoids inhibit the 
indnction of nitric oxide synthase in macrophages. Biochem Biophys Res 
Commun 1 72 : 1 246-1252, 1 990 
19. Paliogianni F, Raptis A, Ahuja SS , Najjar SM, Boumpas DT: Negative transcrip­
tional regulation of human interleukin 2 (1L-2) gene by glucocorticoids 
through interference with nuclear transcription factors AP-1 and NF-AT. ] 
Clin Invest 9 1 : 1 481-1489, 1 993 
20. Northrop ]p, Crabtree GR, Mattila PS: Negative regulation of interleukin 2 
transcription by the glucocorticoid receptor. ] Exp Mea 175:1235-1245, 1992 
2 1 .  Daynes RA, Araneo BA: Contrasting effects of g1ucocorticoids on the capacity of 
T cells to produce the growth factors interleukin 2 and interleukin 4. Eur] 
ImmunoI 19:23 19-23 25, 1989 
22. Naito M, Yusa K, Tsuruo T: Steroid hormones inhibit binding of Vinca alkaloids 
to multidrug resistance related P-glycoprotein. Biochem Biophys Res Commun 
158:1066-1071 , 1 989 
23. Whorwood CB, Franklyn JA, Sheppard MC, Stewart PM: Tissue localization of 
11 ,8-hydroxysteroid dehydrogenase and its relationship to the glucocorticoid 
receptor. ] Steroid Biochem Mol Biot 41:2 1-28, 1992 
24. Mercer WR, Krozowski ZS: Localization of an l 1 {3-hydroxysteroid dehydroge­
nase activity to the distal nephron. Evidence for the existence of two species of 
dehydrogenase in the rat kidney. Elldocrinology 130:540-543, 1992 
25. Philips DM, Lakshmi V, Monder C: Corticosteroid l 1�-dehydrogenase in rat 
testes. Endocrinology 125:209-216, 1989 
26. Moisan M-P, Seckl JR, Edwards CRW: 1 1 ,8-hydroxysteroid dehydrogenase 
bioactivity and messenger RNA expression in rat forebrain: localization in 
hypothalamus, hippocampus, and cortex . Endocrinology 127:1450-1455, 1 990 
27. Teller MN: Interrelationships among aging, immunity and cancer. In: Sigel MM, 
Good RA (eds.). Tolerance, Autoimmunity and Aging. Charles C. Thomas, 
Springfield, IL, 1972, pp 39 -52 
28. Kantor AB, Herzenberg LA: Origin of murine B cell lineages. Annu Rev Immunol 
1 1 : 501-538, 1 993 
29. Daynes RA, Dudley DJ, Araneo BA: Regulation of murine lymphokine produc­
tion in vivo. II. Dehydroepiandrosterone is a natural enhancer ofinterleukin-2 
synthesis by helper T cells. EUT] Immllnol 20:793-802, 1990 
30. Araneo BA, Woods ML n, Daynes RA: Reversal of the immunosenescent 
phenotype by dehydroepiandrosterone: hormone treatment provides an adju­
vant effect on the immunization of aged mice with recombinant hepatitis B 
surtiu:e antigen. ] Infect Dis 167:830-840, 1993 
3 1 .  Daynes RA, Araneo BA, Dowell TA, Huang K, Dudley D: Regulation of murine 
Iymphokine production in vivo. In. The lymphoid tissue microenvironment 
exerts regulatory infiuences over T-helper cell function. ] Exp Med 1 7 1 :979-
996, 1 990 
32.  Garg M, Bondada S: Reversal of age-associated decline in immune response to 
Pnu-imune vaccine by supplementation with the steroid hormone dehydro­
epiandrosterone. I'!feet Immun 61 :223 8 -2241 , 1 993 
33. Caffrey RE, Kapasi ZF, Haley ST, Tew JG, Szakal AK: DHEAS enhances 
germinal center responses in old mice. Adv Exp Med Bioi (in press) 
34. Swenson CD, Arnin AR, Edington J, Gottesman SRS, Thorbecke GJ: The role 
ofIgD-receptors (lgD-R) on T cells in young and aged mice. FASEB] 8 :A749, 
1 994 
3 5 .  Daynes RA, Araneo BA: Programming of lymphocyte responses to activation: 
extrinsic factors, provided microenvironmentallYt confer flexibility and com­
partmentalization to T-cell function. Chem Immunol 54:1-20, 1992 
36.  Daynes RA, Meikle AW, Araneo BA: Locally active steroid hormones may 
facilitate compartmentalization of immunity by regulating the types of lym­
phokines prodnced by helper T cells. Res Immullol 1 42:40-45, 1991 
37. Daynes RA, Araneo BA: The development of effective vaccine adjuvants 
employing natural regulators ofT -cell lymphokine production in vivo. Ann NY 
Acad Sci 730:144 -1 6 1 , 1 994 
38. Marandici A, Monder C: Inhibition by glycyrrhetinic acid of rat tissue 1 1 ,8-
hydroxysteroid dehydrogenase in vivo. Steroids 58:153-1 56, 1 993 
